Drug Type Autologous CAR-T |
Synonyms Anti-CD123 Chimeric Antigen Receptor-Modified Autologous T Cells(Institute of Hematology and Blood Transfusion), Autologous CAR123 T lymphocytes(Institute of Hematology and Blood Transfusion) |
Target |
Action modulators |
Mechanism CD123 modulators(Interleukin-3 receptor subunit alpha modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 1 | Czechia | 23 Oct 2024 | |
CD123 Positive Hematologic Neoplasms | Phase 1 | Czechia | 23 Oct 2024 | |
Myelodysplastic Syndromes | Phase 1 | Czechia | 23 Oct 2024 | |
Refractory acute myeloid leukemia | Phase 1 | Czechia | 23 Oct 2024 |